scholarly journals Post-Traumatic Stress Symptoms in Long-Term Non-Hodgkin's Lymphoma Survivors: Does Time Heal?

2011 ◽  
Vol 29 (34) ◽  
pp. 4526-4533 ◽  
Author(s):  
Sophia K. Smith ◽  
Sheryl Zimmerman ◽  
Christianna S. Williams ◽  
Habtamu Benecha ◽  
Amy P. Abernethy ◽  
...  
Keyword(s):  
Traumatic Stress ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Ptsd Symptoms ◽  
Post Traumatic Stress ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Post Traumatic ◽  
Cancer Experience

Purpose Little is known about the trajectory of post-traumatic stress disorder (PTSD) symptoms in cancer survivors, despite the fact that such knowledge can guide treatment. Therefore, this study examined changes in PTSD symptoms among long-term survivors of non-Hodgkin's lymphoma (NHL) and identified demographic, clinical, and psychosocial predictors and correlates of PTSD symptomatology. Patients and Methods Surveys were mailed to 682 NHL survivors who participated in an earlier survey and now were at least 7 years postdiagnosis. Information was obtained regarding PTSD symptoms, positive and negative perceptions of the cancer experience (ie, impact of cancer), and other potential correlates of PTSD. Results A total of 566 individuals participated (83% response rate) with a median of 12.9 years since diagnosis; respondents were 52% female and 87% white. Although half (51%) of the respondents reported no PTSD symptoms and 12% reported a resolution of symptoms, more than one-third (37%) reported persistence or worsening of symptoms over 5 years. Survivors who reported a low income, stage ≥ 2 at diagnosis, aggressive lymphoma, having received chemotherapy, and greater impact of cancer (both positive and negative) at the initial survey had more PTSD symptoms at follow-up. In multivariable analysis, income and negative impacts of cancer were independent predictors of PTSD symptoms. Conclusion More than one-third of long-term NHL survivors experience persisting or worsening PTSD symptoms. Providers should be aware of enduring risk; early identification of those at prolonged risk with standardized measures and treatments that target perceptions of the cancer experience might improve long-term outcomes.

scholarly journals Post-Traumatic Stress Outcomes in Non-Hodgkin's Lymphoma Survivors

2008 ◽  
Vol 26 (6) ◽  
pp. 934-941 ◽  
Author(s):  
Sophia K. Smith ◽  
Sheryl Zimmerman ◽  
Christianna S. Williams ◽  
John S. Preisser ◽  
Elizabeth C. Clipp
Keyword(s):  
Quality Of Life ◽  
Risk Factors ◽  
Traumatic Stress ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Ptsd Symptoms ◽  
Post Traumatic Stress ◽  
Non Hodgkin's Lymphoma ◽  
Post Traumatic

Purpose A large body of evidence suggests that being diagnosed with and treated for cancer adversely affects functioning and quality of life, yet less is known about longer term outcomes. Therefore, this study aims to estimate the prevalence of post-traumatic stress disorder (PTSD) symptoms in survivors of adult non-Hodgkin's lymphoma (NHL) who are at least 2 years postdiagnosis and identify the risk factors associated with PTSD symptoms, with a focus on those that are amenable for screening and modifiable. Patients and Methods A total of 886 NHL survivors identified from the cancer registries of two hospitals in North Carolina participated, ranging in age from 25 to 92 years old and ranging from 2 to 44 years postdiagnosis. Survivors were mailed a survey that assessed PTSD symptoms and quality of life. Results Participants averaged 10.2 years postdiagnosis, and most (61%) reported no PTSD symptoms. The adjusted prevalence for full PTSD was 7.9%, with an additional 9.1% meeting criteria for partial PTSD. Modifiable risk factors that were independently associated with PTSD in multiple linear regression included less social support, negative appraisals of life threat and treatment intensity, and more employment and insurance issues. Additionally, several demographic characteristics (nonwhite race, less education, and younger age) and clinical or health-related factors (active disease, more recent diagnosis, and more comorbidity) were independently associated with PTSD. Conclusion Although only 8% of survivors met PTSD diagnostic criteria, the impact of a cancer diagnosis and treatment persists for many survivors, as evidenced in 39% of this sample. Early identification of those at risk could enable treatment to minimize PTSD symptomatology.

scholarly journals Association between B Cell Growth Factors and Primary Sjögren’s Syndrome-Related Autoantibodies in Patients with Non-Hodgkin’s Lymphoma

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Zhenhua Xian ◽  
Dehua Fu ◽  
Shuang Liu ◽  
Yang Yao ◽  
Chun Gao
Keyword(s):  
Cell Growth ◽  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Lymphoma Patient ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
B Cell Growth Factor ◽  
Diagnostic Panel

Despite the overall success of using R-CHOP for the care for non-Hodgkin’s lymphoma patients, it is clear that the disease is quite complex and new insight is needed to further stratify the patient for a better personized treatment. In current study, based on previous studies from animal model, new panels combining well-established cytokine (BAFF) and autoantibodies (anti-SSA/Ro) with newly identified cytokine (IL14) and autoantibodies (TSA) were used to evaluate the association between B cell growth factor and Sjögren’s related autoantibodies in NHL patients. The result clearly indicates that there was a unique difference between BAFF and IL14 in association with autoantibodies. While serum BAFF was negatively associated with the presence of both traditional anti-SSA/Ro and novel TSA antibodies in GI lymphoma patient, IL14 was positively associated with the presence of both traditional anti-SSA/Ro and novel TSA antibodies in non-GI lymphoma patient. Long-term follow-ups on these patients and evaluation of their response to the R-CHOP treatment and recurrence rate will be very interesting. Our result provides a solid evidence to support using novel diagnostic panel to better stratify the NHL patients.

scholarly journals IBRUTINIB IN THE MANAGEMENT OF NON-HODGKIN’S LYMPHOMA: A CASE REPORT

2018 ◽  
Vol 11 (12) ◽  
pp. 1 ◽  
Author(s):  
Sree Durga Ts ◽  
Pavithran K ◽  
Uma Devi P
Keyword(s):  
Case Report ◽  
Disease Progression ◽  
Hodgkin’S Lymphoma ◽  
Kinase Inhibitor ◽  
Lymphocytic Leukemia ◽  
Hodgkin's Lymphoma ◽  
Current Case ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Non-Hodgkin’s lymphoma (NHL) is a diverse group of lymphoid neoplasms, the prevalence of which has increased over the past few decades. NHL is diverse in the manner of presentation, response to various treatment and prognosis. The current case report describes a 40-year-old man who was diagnosed with small lymphocytic lymphoma/chronic lymphocytic leukemia in 2006. The patient had disease progression during the course of 10 years from the time of diagnosis for which he received multiple lines of chemotherapy (chlorambucil/prednisolone; rituximab/cyclophosphamide/ fludarabine; bendamustine/rituximab; and ofatumumab). However, in 2016, his disease again showed signs of progression, and hence he was started on ibrutinib 140 mg 3 times daily. After treatment with ibrutinib, there were no clinical nodes and hepatosplenomegaly, and all counts also normalized. Since the commencement of this agent, no disease progression was observed for almost 16 months. However, in July 2017, again disease progression occurred, and the patient was started on with cyclophosphamide, vincristine, and prednisone (COP) regimen. He received one cycle of COP regimen and continued on treatment with ibrutinib, and the treatment was well tolerated. In December 2017, he expired due to the progression of the disease. Ibrutinib, a Bruton’s tyrosine kinase inhibitor, appears to be safe and effective in providing long-term disease control even in refractory cases of NHL.

Childhood non-hodgkin's lymphoma: Long-term results of an intensive chemotherapy regimen

Cancer ◽  
1981 ◽  
Vol 48 (7) ◽  
pp. 1508-1512 ◽  
Author(s):  
Marco Gasparini ◽  
Fabrizio Lombardi ◽  
Franca Fossati Bellani ◽  
Cristina Gianni ◽  
Silvana Pilotti ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Chemotherapy Regimen ◽  
Hodgkin's Lymphoma ◽  
Long Term Results ◽  
Intensive Chemotherapy ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma
Sign in / Sign up

Export Citation Format

Share Document